Trials / Completed
CompletedNCT01247272
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Teva Pharmaceuticals USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluoxetine Hydrochloride | 90 mg Capsules |
| DRUG | PROZAC WEEKLY® | 90 mg Capsules |
Timeline
- Start date
- 2001-05-01
- Primary completion
- 2001-07-01
- Completion
- 2001-07-01
- First posted
- 2010-11-24
- Last updated
- 2011-02-21
- Results posted
- 2011-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01247272. Inclusion in this directory is not an endorsement.